Nursing Leadership Health Policy
Health Policy Change
The health policy change encompasses Medicare Part D. Medicare D. is also referred to as the Medicare prescription drug benefit. It is part of the Medicare program that is purposed to bankroll the cost of prescription drugs together with coverage payments for prescription drugs for Medicare recipients (Centers for Medicare & Medicaid Services, 2016). The proposed policy change with respect to Medicare Part D is the reduction and lessening of generic drug copayments to zero. In particular, this alteration will be a form of encouragement for the use of generic drugs amongst Medicare enrollees that are poorer by all in all eradicating their costs for generic drugs. Majority of the members of Medicare Part D that are categorized as having low income give out minimal compensation or nil for Part D prescription drugs. In the past year, with respect to generics, the costs varied between $1.20 and $2.95 whereas for brands, the costs varied from $3.60 to $7.40. It is imperative to note that health care plans are not able to place levels or rank medications of most of the members in Medicare Part D similar to how it is undertaken in other kinds of health care plans in the Affordable Care Act or commercial markets. The implication of this is that it causes members to move in the direction of treatment options that have more value or impact for their
By eradicating copayments for generic drugs as well as some sought after brand drugs, it implies that Medicare plans will be able to make certain that those who enroll spend federal funds in a sensible and prudent manner while gaining accessibility to cost-effective health care. Several Medicare members that have low income, that would feel the deemed minimal $2.95 copayment to be a financial encumbrance, would largely benefit by not having to pay anything at all for obtaining their generic and cost-effective brands of prescribed medication. In turn, this will give rise to augmented adherence to medication by the members. Taking this into consideration, the small group of Medicare members of low income that would opt to go on utilizing brand medications that are not preferred, would have to give out greater payments for such treatments that are less cost-effective (Schultz, 2016).
From my own perspective, adequate safeguard have been put in place for such Medicare members for the reason that there will be an already set up exemption procedure if it turns out that a less costly medication is not clinically suitable for a Medicare Part D member. Decreased federal spending and higher financial accountability for Medicare Part D members would be beneficial in getting rid of those generic copayments.
Exact Wordings
Concerns:…
The Act creates a positive balance between government interests to save money and the interests of Medicare recipients to receive a wide range of drugs for their specific needs. The current ban on government negotiations with pharmaceutical companies serves to protect Medicate recipients by using the positives of the free market, such as the experience and purchasing power of PBMs. While there are serious potential problems with this approach,
(2003) that examined the access that black and Hispanic Medicare beneficiaries have to prescribe drugs for chronic conditions. Not much has changed in the times since then and taking the findings of the study it can be established that the Black and Hispanic Medicare beneficiaries are subject to medication under use for economic reasons. This is also true for the chronically-ill black and Hispanic beneficiaries, who require constant medication
Pharmacy Ethics The author of this report has been asked to review the legal and ethical considerations in play given the test case scenario surrounding Pharmacare and Compcare. As is quickly apparent while reading the case study, the company engaged in a long and extensive list of ethical and/or legal violations as a means to maximize profit and minimize the legal and other red tape that seems to bother them even
CASE STUDY: IMPORTING DRUGS TO US Case Study: Importing Drugs to US7-3: Should the United States legalize the importation of lower cost pharmaceuticals? If so, should this apply to individual consumers, pharmacies, or other entities?The US should legalize the importation of lower-cost pharmaceuticals from selected countries with testing and licensure requirements similar to those of the FDA. Strict conformity to US standards for handling and manufacturing prescriptions would ensure that
While it is definitely true that these companies spend a great deal of money on research and development, for which they certainly deserve and in fact need to be compensated (not to mention their right to make a profit, and the fact that profit potential is a major driver in innovation), the amount of profit and compensation that comes solely from the United States is inordinate when compared to
President George Bush proposed a two part strategy with initial implemented drug coverage to low-income beneficiaries coupled with a White House task force to develop a plan to reform Medicare (Health Policy, 2001). Under this plan beneficiaries with income 135% below the national poverty guidelines would be eligible for full prescription drug coverage and a sliding scale would be provided for those under 175% (Health Policy 2001). The most controversial
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now